Status:

NOT_YET_RECRUITING

Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients

Lead Sponsor:

Changhua Christian Hospital

Collaborating Sponsors:

China Medical University, Taiwan

Conditions:

Diabetes

Eligibility:

All Genders

20-80 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to learn the potential of bitter melon peptides in stabilizing blood glucose in diabetic adults. It will also learn about the effects of bitter melon peptides on met...

Eligibility Criteria

Inclusion

  • Participants were diagnosed with type 2 DM based on criteria recommended by the American Diabetes Association and required to have fasting plasma glucose of ≥126 mg/dl or an HbA1c of
  • ≥ 6.5%, as measured on two separate occasions

Exclusion

  • cancer, active liver disease, current pregnancy , acute illness and autoimmune thyroid disease.

Key Trial Info

Start Date :

May 27 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 26 2026

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT06970834

Start Date

May 27 2025

End Date

March 26 2026

Last Update

May 14 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients | DecenTrialz